AI Article Synopsis
- Lung adenocarcinoma can show various radiological features, but diffuse cystic lesions in both lungs are very uncommon.
- A case study is presented about a middle-aged woman diagnosed with lung adenocarcinoma, which was confirmed through histopathological analysis after showing diffuse cystic lesions.
- The patient was treated with the EGFR inhibitor Gefitinib and maintained stability for 18 months, highlighting the importance of recognizing rare imaging patterns to avoid misdiagnosis.
Article Abstract
Lung adenocarcinoma can exhibit a variety of radiological manifestations. However, the presence of diffuse cystic lesions in both lungs is extremely rare. Here, we report a case of a middle-aged woman with a primary lung adenocarcinoma that manifested as diffuse cystic lesions in bilateral lungs. Histopathological examination ultimately confirmed the lung adenocarcinoma. The patient was treated with the epidermal growth factor receptor (EGFR) inhibitor Gefitinib and remained stable during 18 months of follow-up. Knowledge of uncommon radiological performances of lung adenocarcinoma characterized by diffuse cystic imaging is important in suggesting the diagnosis and preventing misinterpretation.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966008 | PMC |
Publication Analysis
Top Keywords
Similar Publications
Evaluation of an enhanced ResNet-18 classification model for rapid On-site diagnosis in respiratory cytology.
BMC Cancer
January 2025
Department of Pathology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325000, Zhejiang, China.
Objective: Rapid on-site evaluation (ROSE) of respiratory cytology specimens is a critical technique for accurate and timely diagnosis of lung cancer. However, in China, limited familiarity with the Diff-Quik staining method and a shortage of trained cytopathologists hamper utilization of ROSE. Therefore, developing an improved deep learning model to assist clinicians in promptly and accurately evaluating Diff-Quik stained cytology samples during ROSE has important clinical value.
View Article and Find Full Text PDFAidi injection inhibits the migration and invasion of gefitinib-resistant lung adenocarcinoma cells by regulating the PLAT/FAK/AKT pathway.
Chin Med
January 2025
Department of Clinical Chinese Pharmacy, School of Chinese Materia Medica, Beijing University of Chinese Medicine, Beijing, 102488, China.
Background: With extended gefitinib treatment, the therapeutic effect in some non-small cell lung cancer (NSCLC) patients declined with the development of drug resistance. Aidi injection (ADI) is utilized in various cancers as a traditional Chinese medicine prescription. This study explores the molecular mechanism by which ADI, when combined with gefitinib, attenuates gefitinib resistance in PC9GR NSCLC cells.
View Article and Find Full Text PDFNew thiazole derivative as a potential anticancer and topoisomerase II inhibitor.
Sci Rep
January 2025
Chemistry Department, Faculty of Science, Damietta University, Damietta, New-Damietta, 34517, Egypt.
To shed light on the significance of thiazole derivatives in the advancement of cancer medication and to contribute to therapeutic innovation, we have designed the synthesis and antiproliferative activity investigation of 5-(1,3-dioxoisoindolin-2-yl)-7-(4-nitrophenyl)-2-thioxo-3,7-dihydro-2H-pyrano[2,3-d] thiazole-6-carbonitrile, the structure of thiazole derivative was confirmed by spectroscopic techniques UV, IR and NMR. The cytotoxic activity (in vitro) of the new hybrid synthesized compound on five human cancer cell lines; human liver hepatocellular carcinoma (HepG-2), colorectal carcinoma (HCT-116), breast adenocarcinoma (MCF-7), and epithelioid carcinoma (Hela), and a normal human lung fibroblast (WI-38) was studied using MTT assay. The compound exhibited a strong cytotoxicity effect against HepG-2 and MCF-7.
View Article and Find Full Text PDFClassification of non-TCGA cancer samples to TCGA molecular subtypes using compact feature sets.
Cancer Cell
December 2024
Department of Epigenetics, Van Andel Institute, Grand Rapids, MI 49503, USA. Electronic address:
Molecular subtypes, such as defined by The Cancer Genome Atlas (TCGA), delineate a cancer's underlying biology, bringing hope to inform a patient's prognosis and treatment plan. However, most approaches used in the discovery of subtypes are not suitable for assigning subtype labels to new cancer specimens from other studies or clinical trials. Here, we address this barrier by applying five different machine learning approaches to multi-omic data from 8,791 TCGA tumor samples comprising 106 subtypes from 26 different cancer cohorts to build models based upon small numbers of features that can classify new samples into previously defined TCGA molecular subtypes-a step toward molecular subtype application in the clinic.
View Article and Find Full Text PDFCorrection to "Olink Proteomics-Based Exploration of Immuno-Oncology-Related Biomarkers Leading to Lung Adenocarcinoma Progression".
J Proteome Res
January 2025
Department of Thoracic Surgery, Ningbo No.2 Hospital, Ningbo, 315010 Zhejiang, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!